Geron Corporation (NASDAQ:GERN) Q3 2019 Earnings Conference Call Transcript

Nov 07, 2019 • 08:00 am ET

Previous

Geron Corporation (NASDAQ:GERN) Q3 2019 Earnings Conference Call Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Ladies and gentlemen thank you for standing by and welcome to the Third Quarter 2019 Geron Earnings Conference Call. [Operator Instructions]

I would now like to hand the conference over to your speaker today Suzanne Messere. Please go ahead.

Executive
Suzanne Messere

Thank you Lisa and good morning everyone. Thank you for joining us for our third quarter conference call. I am joined today by Dr. John Scarlett Geron's Chairman and Chief Executive Officer; Olivia Bloom the company's CFO; and Dr. Aleksandra Rizo our Chief Medical Officer. After the market closed yesterday we announced our third quarter 2019 financial results via press release and is available on our website under www.geron.com/investors. This morning management will discuss information from yesterday's press release. A live webcast of the call is available on our website and will be archived for 30 days. Before we begin please note that except for statements of historical fact this presentation and question-and-answer session contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements include any of the company's plans expectations timelines believes statements of potentiality and projections and without limitation those regarding that the top line results from the Phase III portion of IMerge are expected to be available by midyear 2022 that there will be an end of Phase II meeting with the FDA by the end of first quarter 2020 that Geron may potentially develop telaprevir relapsed/refractory MF patients and that Geron's 2019 operating expenses will be $80 million to $85 million.

All of these forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties include without locations those regarding that the company may be unable to overcome all the clinical safety efficacy technical scientific operational manufacturing and regulatory challenges to enable the top line results from the Phase III portion of IMerge to be available by midyear 2022. The regulatory authorities may not comment the further development of imetelstat on a timely basis or at all. That the company may decide not to develop Intelsat for relapsed/refractory MF patients and that there may be unexpected operating expenses or event that caused the $80 million to $85 million 2019 financial guidance to be revised. Detailed information on the votes and uncertainties and additional risks uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are into the heading Risk factors in Geron's quarterly report on Form 10-Q for the quarter ended September 30 2019 filed with the SEC. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. And the facts and assumptions underlying the forward-looking statements may change. Except as required by law churn disclaims any obligation to update these forward-looking statements to reflect future information events or circumstances.

With that I'd like to turn the call over to Dr. John Scarlett